Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BOVEN Regimen in Previously Untreated CLL, SLL, and MCL
NCT03824483Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2019
- Primary completion
- Feb 2027
- Modality
- Fragment-Derived Small Molecules, Antibody Conjugates, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zanubrutinib, obinutuzumab and venetoclax in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and mantle cell lymphoma (MCL), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Rate of Minimum Residual Disease (MRD) Undetectable Response at 1 year. Started Feb 2019; status: active, not recruiting.
02
Drugs
zanubrutinibobinutuzumabvenetoclax
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03824483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03824483.